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82.1% initially diagnosed at stage IV. Common sites of metastasis were bone (41.1%), 
brain (23.2%), contralateral lung (19.0%), and liver (15.8%). 24.2% were current smok-
ers; 67.4% past (median 38 pack years). There were no differences in these character-
istics by regimen. The most common comorbidities were COPD (30.5%) and diabetes 
(16.8%). Most patients were from the South (56.8%) vs. Northeast (13.7%), Midwest 
(21.1%), and West (8.4%). Patients from the South were 3 times as likely (OR = 3.02) 
to receive a bevacizumab-containing regimen (Regimens B+D) than patients from 
the non-South regions, χ 2 = 6.5293, df = 1, p = 0.0106. ConClusions: Patients treated 
for advanced NSCLC in real world settings appear demographically and clinically 
similar to patients treated in clinical trials. Preliminary findings suggest regional 
differences in chemotherapeutic treatment patterns.
CARDIOVASCULAR DISORDERS – Clinical Outcomes Studies
PCV1
LIPID-LOwERIng ThERAPy wITh STATInS MAy BE ASSOCIATED wITh 
CATARACT AnD CATARACT OPERATIOn RISkS
Ali A.K.
Eli Lilly and Company, Indianapolis, IN, USA
objeCtives: There has been an increasing concern about the link between statins 
and the risk for cataract. This study detects and clarifies signals of cataract forma-
tion and operation associated with lipid-lowering drugs (LLD), including statins, from 
postmarketing adverse event reports. Methods: A pharmacovigilance analysis 
of adverse events submitted to the FDA Adverse Event Reporting System between 
Oct1997 and Sep2012 was conducted. Multi-item Gamma Poisson Shrinker algorithm 
was applied to detect signals of cataract and cataract operation. Empirical Bayes 
Geometric Mean (EBGM) and corresponding 95%CI (EB05-EB95) were estimated for 
drug-event combinations of interest. Estimates with EB05≥ 2 are significant dispro-
portional reporting of the event for LLD. The MedDRA Preferred Term hierarchy was 
used to define events, and generic name of the reported drug was used to define LLD 
exposure. Results: 1,195 cataract and 99 cataract operation reports were submitted 
for LLD (respectively, 94% and 95% of these reports were for statins). Most of cataract 
reports were for lovastatin (n= 399) and most of cataract operation reports were for 
atorvastatin (n= 68). Among LLD, cataract signal was detected for statins (EBGM 3.64, 
EB05-EB95 3.18-4.2). Among statins, lovastatin was associated with the strongest sig-
nal for cataract formation (EBGM 12.8, EB05-EB95 11.8-14.0), followed by pravastatin 
(EBGM 3.82, EB05-EB95 3.21-4.53) and atorvastatin (EBGM 2.95, EB05-EB95 2.7-3.21). No 
cataract operation signal was detected for any LLD class, including statins (EBGM 1.52, 
EB05-EB95 1.08-2.36); however, cataract operation signals were detected for rosuvas-
tatin (EBGM 3.82, EB05-EB95 3.21-4.53) and atorvastatin (EBGM 3.33, EB95-EB95 2.72-
4.05). Disproportional reporting of cataract with EB05> 1 was found for simvastatin 
(EB05= 1.66), fluvastatin (EB05= 1.34) and gemfibrozil (EB05= 1.32). ConClusions: 
Antilipemic treatment with statins may be associated with an increased risk of cata-
ract development or operation. Statin users with risk factors for cataract formation 
should have routine ophthalmic examination for lenticular opacity, and alternative 
LLD should be used in high-risk individuals.
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EffECT Of PRASUgREL VS CLOPIDOgREL On hOSPITAL READMISSIOn AMOng 
ACUTE COROnARy SynDROME PATIEnTS TREATED wITh PRASUgREL
Olson W.H.1, Ma Y.W.2, Lefebvre P.3, Laliberté F.3, Crivera C.1, Schein J.R.1, Fields L.E.2, Dea K.3, 
Germain G.3, Lynch S.M.4
1Janssen Scientific Affairs, LLC, NJ, USA, 2Janssen Pharmaceuticals Inc., NJ, USA, 3Groupe 
d’analyse, Ltée, Montréal, QC, Canada, 4Department of Sociology, Princeton University, Princeton, 
NJ, USA
objeCtives: During the last decade, the standard of care to treat acute coronary 
syndrome (ACS) patients was typically a combination of clopidogrel and aspirin. 
However, newer antiplatelet agents were approved recently. The aim of this study 
was to assess the effect on time-to-readmission and resource utilization of prasu-
grel vs. clopidogrel in prasugrel treated patients after hospitalization with an ACS 
event. Methods: Based on the Truven Health Analytics MarketScan database 
from January 2009 through July 2012 a matched-cohort was created. Inferences 
for average treatment effect on time-to-readmission and numbers of hospitaliza-
tions, ER visits, and outpatient visits in prasugrel treated patients at 30 days and 
1 year were performed by (1) frequentist Kaplan-Meier estimation with a log-rank 
test and Lin’s method for censored resource utilization outcomes; and (2) Bayesian 
discrete-time hazard models and negative binomial models. Bayes factors were 
also determined. Results: 10,963 matched-pairs were well-balanced on baseline 
characteristics. Frequentist analyses of time-to-readmission at 1 year and resource 
utilization rates over 30 and 365 days showed no statistical differences between 
prasugrel and clopidogrel (log-rank test and Lin method p-values all > 0.05 ). The 
posterior probability of equivalence between drugs for time-to-readmission at a 
margin of 10% was 98.7%, and based on the Bayes factor for superiority there is 
little evidence of superiority. Based on Bayesian analyses of resource utilization 
outcomes there are high probabilities of equivalence at a margin of 10% and little 
evidence of superiority for all outcomes except for number of hospitalizations at 30 
days, for which there is positive evidence that clopidogrel is superior to prasugrel, 
although the probability that prasugrel is non-inferior to clopidogrel at the 10% 
margin is 0.765. ConClusions: ACS patients treated with prasugrel had time-to-
readmission and resource utilization outcomes equivalent to what they would have 
been if treated with clopidogrel.
PCV3
COMPLICATIOnS RELATED TO CARDIAC RhyThM MAnAgEMEnT DEVICES 
(CRMD’S) ThERAPy AnD ThEIR fInAnCIAL IMPLICATIOn:A PROSPECTIVE 
SIngLE-CEnTER TwO yEARS SURVEy
Fanourgiakis J., Simantirakis E., Kanoupakis E., Chrysostomakis S., Chlouverakis G., Vardas P.
University of Crete, Heraklion, Greece
objeCtives: Cardiac rhythm management devices (CRMD’s) have proven their clini-
cal effectiveness for patients with heart rhythm disorders. Little is known about 
safety and complication rates during implantations of these devices. This study 
demonstrated the complications rates related to implantations of CRMD’s, and 
estimated the additional hospital stay and cost associated with managing these 
complications. Methods: During a period of one year in total 464 consecutive 
recipients were subjected to CRMD’s implantation and furthermore were recruited 
and followed up for 2 years. Finally, data were analyzed for 398 patients who com-
pleted the two year’s follow up, resulting in a total of 796 patient-years. Results: 
From the 201 patients with initial pacemaker (PM) implantations, 6 (2,99 %) patients 
had seven complications (5 patients had lead’s dislodgement, 1 of them twice and 1 
patient developed pocket infection), while from the 117 PMs replacements 1 (0,85 %) 
patient developed a complication (pocket erosion). 2 patients with complication (1 
with an initial PM and 1 with replacement) died before they complete the follow up 
from reasons unrelated to cardiac causes. There weren’t any complications neither 
in initial implantations (69 patients) nor in replacements (11 patients) of implant-
able cardioverter defibrillator (ICD). The average prolongation of the hospital stay 
was 7 days ranging from 1 to 35 days, resulting in 17.411 € of total additional direct 
hospital cost. ConClusions: This study provides relatively low rates of compli-
cations in patients subjected to PMs implantation, initial or replacement, in our 
center compared with others studies. In the case of ICD implantations, initials or 
replacements, there weren’t any complication. The additional hospitalization days 
and cost attributed to these complications depends on the nature of complication.
PCV4
hOSPITAL LEngTh Of STAy: DOES RIVAROxABAn REDUCE InPATIEnT STAy 
COMPARED TO wARfARIn AMOng PATIEnTS wITh nOn-VALVULAR ATRIAL 
fIBRILLATIOn?
Laliberté F.1, Pilon D.1, Raut M.2, Nelson W.W.2, Olson W.H.3, Germain G.1, Schein J.R.3,  
Lefebvre P.1
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 
3Janssen Scientific Affairs, LLC, NJ, USA
objeCtives: Unlike rivaroxaban, warfarin requires laboratory monitoring to docu-
ment achievement of international normalized ratio goal, thereby potentially pro-
longing a patient’s hospital length of stay (LOS). The study objective was to compare 
hospital LOS among hospitalized non-valvular atrial fibrillation (NVAF) patients 
using rivaroxaban versus warfarin in a real-world setting. Methods: A retrospec-
tive claims analysis was conducted using the Premier Perspective Comparative 
Hospital Database from 11/2010 to 9/2012. Adult patients were included in the study 
if they had an index hospitalization for NVAF. Patients initiating rivaroxaban dur-
ing hospitalization were matched with up to 4 warfarin users by propensity score 
analyses. Similar matched sub-analyses were conducted for patients who (1) had 
pre-treatment use of parenteral anticoagulants, and (2) were administered their oral 
anticoagulants on day 3 of their hospital stay or later. Comparison of hospital LOS 
was assessed using generalized estimating equations. Results: The characteristics 
of the matched cohorts were well balanced. Among the matched rivaroxaban and 
warfarin users (2,809 and 11,085 patients, respectively), the mean age of the cohorts 
was 71 years and 49% were females. The average [median] hospital LOS for rivaroxa-
ban patients was 4.5 [3] days compared to 5.3 [4] days for the warfarin cohort. The 
mean difference in hospital LOS of 0.81 days was found to be significant at p< 0.01. 
In the sub-analyses of patients with pre-treatment use of parenteral anticoagulants, 
the average hospital LOS was found to be 1.38 days shorter (p< 0.01) for the rivar-
oxaban group as compared to the warfarin group. Patients who were administered 
rivaroxaban on day 3 of their hospital stay or later had a 1.72 day shorter LOS as 
compared to their matched warfarin counterparts (p< 0.01). ConClusions: This 
study suggests that NVAF patients receiving rivaroxaban have significantly lower 
hospital length of stay as compared to patients receiving warfarin.
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Schein J.R.4, Lefebvre P.1
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objeCtives: Rivaroxaban was shown to be effective in reducing the risk of stroke 
and systemic embolism in patients with nonvalvular atrial fibrillation (AF) in a 
randomized controlled trial setting. The study objective was to assess real-world 
safety, effectiveness, and persistence of rivaroxaban and warfarin in nonvalvular AF 
patients. Methods: Health care claims from Symphony Health Solutions’ Patient 
Transactional Datasets from 5/2011-7/2012 were analyzed. Adult patients newly 
initiated on rivaroxaban or warfarin, with ≥ 2 AF diagnoses (ICD-9-CM: 427.31), and 
a CHADS2 score ≥ 1 during the 180-day baseline period were included. Cohorts 
were matched 1:4 using propensity score methods. Study outcomes were major 
bleeding, intracranial hemorrhage (ICH), gastrointestinal (GI) bleeding, composite 
stroke and systemic embolism, and venous thromboembolism (VTE) events (deep 
vein thrombosis [DVT] and pulmonary embolism [PE]). Cox proportional hazard 
models were used to compare event and persistence rates. Results: The matched 
sample included 3,654 rivaroxaban and 14,616 warfarin patients. Matching was 
adequate, with all standardized differences in patient characteristics < 10%. Mean 
age of both cohorts was 73 years; 51% were female. The mean (SD) drug exposure 
for the rivaroxaban and warfarin cohorts was 83 (58.0) and 114 (70.2) days, respec-
tively. No significant differences were observed for bleeding, and the composite 
stroke and systemic embolism outcomes, although rivaroxaban users were associ-
ated with significantly fewer VTE events (hazard ratio [HR] = 0.46, 95% confidence 
interval [CI]: 0.23-0.91, p= 0.0250) compared to warfarin users. Rivaroxaban was also 
associated with a significantly lower risk of treatment non-persistence (HR= 0.66; 
95%CI: 0.60-0.72, p< 0.001). ConClusions: This analysis suggests that rivaroxaban 
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and warfarin do not differ significantly in real-world rates of composite stroke 
and systemic embolism and major, intracranial, or GI bleeding. Rivaroxaban was 
associated with significantly fewer VTE events and better treatment persistence 
compared with warfarin.
PCV6
RISk Of nEw OnSET DIABETES wITh ROSUVASTATIn ThERAPy AnD QUALITy 
Of LIfE
Siwak A, Khan A., Gut M., Rasty S., Sakharkar P.
Roosevelt University College of Pharmacy, Schamburg, IL, USA
objeCtives: Statins have been shown to significantly reduce the cardiovascular 
risk. In recent studies, high potency statins have been associated with elevated fast-
ing plasma glucose (FPG) and glycated hemoglobin A1c (HbA1c) level. Rosuvastatin is 
widely prescribed statin medication for treating dyslipidemia. A systematic review 
was conducted to examine rosuvastatin’s effect on glycemia levels and quality of 
life. Methods: Double-blind, randomized, clinical trials reporting changes in FBG, 
HbA1C, incidence of new onset diabetes and quality-adjusted life years (QALYs) 
with rosuvastatin therapy were included in this systematic review. Studies that 
were open label, non-randomized, observational, with combination therapies; case 
reports, less than four weeks duration and published in other than English language 
were excluded. Search was performed using MEDLINE, PubMed, Google scholar 
and Cochrane Central Register for Controlled Trials (CENTRAL) using key words 
and MeSH terms through July 2013. Results: From the total of 535 clinical and 
16 health outcomes studies, three clinical (n = 24,714; rosuvastatin arm = 12,332) 
and four outcomes studies met the inclusion criteria. The mean study follow up 
ranged from 1.9 to 3.9 yrs. Incidence of diabetes was reported in 595 (4.8%) patients 
in rosuvastatin arm compared to 519 (4.2%) in placebo arm (RR 1.15, 95% CI 1.026-
1.291). Only one study reported median change in FPG (4mg/dl) and HbA1c (0.2%) 
on two years of therapy. QALYs gained over a lifetime with rosuvastatin therapy 
in patients with Framingham risk score (FRS) ≤ 10% was estimated 0.14, FRS> 10% 
0.33, and with FRS> 20% 0.42 per patient, respectively. Rosuvastatin therapy for pri-
mary or secondary prevention of cardiovascular events in a high-risk population 
showed more QALYs gained compared to low-risk patients from the health system 
perspective. ConClusions: Overall, there was an increase in new onset diabetes 
with rosuvastatin therapy. However, the benefit of reducing cardiovascular risk and 
improved quality of life with rosuvastatin therapy outweighs the risk of diabetes.
PCV7
RISk Of DIABETES In PATIEnTS On ATORVASTATIn ThERAPy fOR TREATIng 
hyPERChOLESTEROLEMIA
Khan A, Gut M., Siwak A., Rasty S., Sakharkar P.
Roosevelt University College of Pharmacy, Schaumburg, IL, USA
objeCtives: Statins have been shown to significantly reduce the risk of heart attack 
and heart disease. However, in recent studies, they were found to raise blood sugar 
levels resulting in diabetes. Atorvastatin is most widely prescribed medication 
among statins for treating hypercholesterolemia. A systematic review of randomized 
clinical trials (RCTs) was conducted to evaluate Atorvastatin’s effect on glycemia 
levels and incidence of diabetes. Methods: MEDLINE, PubMed, Google Scholar and 
Cochrane Central Register of Controlled Trials (CENTRAL) were searched through 
July 2013. RCTs that evaluated Atorvastatin in patients with hypercholesterolemia 
and reported at least one of the following: glycated hemoglobin (HbA1c), fasting 
blood glucose and new onset of diabetes were included. Studies that were open 
label, shorter than four weeks, and published in other than English language were 
excluded. The primary outcome measures were change from baseline in fasting 
glucose, HbA1c level and/or development of diabetes. Results: The final analysis 
of this systematic review included four RCTs out of 104 full text articles retrieved 
that met our inclusion criteria. The sample size in these studies ranged from 3,806 
to 7,461 with a follow up ranging from 2 to 4.9 years. The change from baseline 
fasting blood glucose ranged between 8 to 10.6mg/dL and the incidence of new 
onset diabetes reported ranged from 4.2% to 9.3%. Atorvastatin doses studied were 
40 and 80mg. Studies included in this systematic review showed high degrees of 
heterogeneity in data reporting and analyses. ConClusions: Use of Atorvastatin 
in these studies showed a significant increase in fasting blood glucose and devel-
opment of diabetes. However, high degree of study heterogeneity limited finding’s 
generalizability to a larger population. Atorvastatin’s cardiovascular benefit still 
clearly outweighs the potential risk of reported incident diabetes. Physicians should 
weigh the risks and benefits when prescribing Atorvastatin for their patients in 
treating hypercholesterolemia.
PCV8
ESTIMATIng ThE RISk Of AngIOEDEMA ASSOCIATED wITh USE Of 
DIPEPTIDyL-PEPTIDASE InhIBITORS
Ramachandran S.
University of Mississippi, University, MS, USA
objeCtives: To estimate the risk of angioedema and angioedema related side-
effects caused by the use of dipeptidylpeptidase inhibitors(DPP-4), angiotensin con-
verting enzyme inhibitors (ACEI) and their interaction in patients suffering from 
diabetes and/or hypertension. Methods: A retrospective analysis employing a 
case control design was performed using Mississippi Medicaid fee-for-service data 
from January 1st 2008 to December 31st 2012. Beneficiaries using oral anti-diabetics 
or anti-hypertensives were included in the study. Angioedema was identified using 
ICD-9-CM codes in the medical claims dataset. Beneficiaries with and without an 
incidence of angioedema were matched based on age, sex, race and whether they 
had diabetes or hypertension. Drug use was analyzed in the 180 days before the 
incidence of angioedema. Results: A total of 1,109 cases and 1,109 controls were 
obtained. Women comprised nearly 70% of the population after matching the cases. 
62% of the population was African American and nearly 30% was Caucasian. 8% of 
the population had diabetes only and approximately 15% had both diabetes and 
hypertension. 77% of the population was identified as having only hypertension. 
Only seven controls and none of the cases were found to be using DPP-4s, either 
alone or along with ACEI, in the study period. None of the patients on DPP-4s had 
an incidence of angioedema. No evidence was found to support the hypothesis that 
DPP-4s increase the incidence of angioedema when used alone or in combination 
with ACEIs. ConClusions: All cases of angioedema that were found in patients 
who were using DPP-4s, did not have the temporal association that is required to 
establish some degree of correlation, if not causality. However, this study can only 
predict that if there were cases of DPP-4s induced angioedema, they could not be 
identified. Any chances of angioedema caused by DPP-4s themselves or an interac-
tion between DPP-4s and ACEIscould not be established by this study.
PCV9
PREDICTIOn Of nEwLy DIAgnOSED ATRIAL fIBRILLATIOn wITh CO-
MORBIDITy TO ThE MAjOR ADVERSE CARDIOVASCULAR EVEnT: A 
nATIOnwIDE DATABASE OUTCOME RESEARCh In TAIwAn
Li C.Y.1, Lin C.P.2, Chien L.1, Lin Y.J.3, Chen L.L.C.1, Chu P.H.2, Chang C.J.1
1Chang Gung University, Tao-Yuan, Taiwan, 2Chang Gung Memorial Hospital, Tao-Yuan, Taiwan, 
3Chang Gung University, Taoyuan, Taiwan, Taiwan
objeCtives: Atrial Fibrillation (AF) is the most common cardiac arrhythmia for 
adults. It may cause severe health problems, and is associated with significant mor-
bidity and resulting high mortality. We investigated the hazard ratios (HR) of major 
adverse cardiovascular events (MACE) between new-diagnosed AF (NDAF) with dif-
ferent comorbidities and non-AF subjects without any comorbidity. Methods: 
Data extracted from the National Health Insurance Research Database for this 
observational retrospective cohort study between 2006 and 2010. Using 1 to 4 pro-
pensity score matching method, it resulted with 3,737 NDAF patients and 14,948 
non-AF patients. The baseline comorbidity of hypertension (HTN), diabetes mellitus 
(DM), dyslipidemia, gender, and age (65 years) were used in the matching process. 
Log rank test and Cox proportion hazard models were used to estimate and to 
predict the HR of risk factors associated with MACE. Results: After propensity 
score matching, there was no baseline demographic characteristics difference in 
patients between NDAF and non-AF groups. There is a statistical significance of 
MACE between NDAF and non-AF with HR = 3.4, 95% C.I.of (3.2, 3.6), p < 0.0001. 
When comparing to the non AF subjects without any comorbidity, the HRs were 
8.45, 8.71, 12.27, and 12.42 for NDAF alone, NDAF with Dyslipidemia, DM, and HTN, 
respectively. All p values < 0.0001. Moreover, the HR of MACE between NDAF with 
all three comorbidities comparing to non-AF without any comorbidity resulted in 
a higher HR of 13.54. ConClusions: This study has demonstrated that NDAF risk 
alone is highly associated with a higher risk of MACEs as compared to those without 
AF. After adjusting age and gender, NDAF, with known comorbidity HTN, DM and 
Dyslipidemia, will have even higher risk for MACE outcome.
PCV10
USIng ThE CLALIT hEALTh SERVICES ELECTROnIC MEDICAL RECORD 
DATABASE fOR SAfETy RESEARCh: A fEASIBILITy CASE STUDy
Feldman B.1, Hoshen M.B.1, Brody J.2, Balicer R.D.3
1Clalit Research Institute, Tel Aviv, Israel, 2Kantar Health, New York, NY, USA, 3Clalit Health 
Services, Tel Aviv, Israel
objeCtives: Previous published criticisms of safety studies based on secondary 
databases suggest significant methodological flaws, including substantial missing 
data, biased diagnoses, outcome under-reporting, and poor transparency in data 
analytics. Clalit Health Services (CHS) is a payer-provider comprehensive health 
fund, with 4 million members. The administrative and clinically-oriented CHS 
database encompasses a decade of integrated inpatient, outpatient, laboratory and 
pharmacy data. Leveraging published safety studies of the association between 
the risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) 
among Oral Contraceptives (OCs) users of differing progestogens, we tested if the 
comprehensiveness of the CHS’ EMR database could overcome prior criticisms of 
secondary database-conducted safety studies. Methods: Data for all CHS female 
members aged 15-49 were accessed. A retrospective cohort study design 1.2008-
6.2013 identified new OC users in 2008, following-up until study period end. VTE and 
ATE incidence was determined and Cox-regression models estimated time-to-event 
across OC groups. RESULTSAmong 755,824 women in 2008, 94,792 new OC users were 
identified using comprehensive pharmacy dispensing data. Monthly demographic 
data and periodically measured clinical data (like BMI and smoking) are recorded 
following strict quality measures, resulting in only 9.5% missing smoking status 
and 2.1% missing BMI values among this sample. Community-based and hospital 
EMRs are centrally collated. Cardiovascular outcomes were validated via patient 
file review. As VTE-related hospitalization is independent of gynecologist referral 
we expect minimal bias on this account. Symptomatic effects requiring interven-
tion are fully reported as cost-related procedures. Out-of-pocket copayments are 
minimal, not predisposing against referrals. Transparency and quality are assured 
by detailed epidemiology and biostatistics protocols followed explicitly, statistical 
programming using cross-checked validated code and peer-reviewed statistical 
analyses ConClusions: As a result of unique historical circumstances and policy 
decisions, Clalit’s comprehensive and integrated data warehouse was able to over-
come previously identified flaws in secondary databases for use in safety studies.
PCV11
RISk Of VEnOUS ThROMBOEMBOLISM ASSOCIATED wITh AnTIPSyChOTIC 
USE AMOng POSTMEnOPAUSAL wOMEn
Wang M.T.1, Chu C.L.1, Huang Y.W.2
1National Defense Medical Center, Taipei, Taiwan, 2National Defense Medical Center, Tri-service 
General Hospital, Taipei, Taiwan
objeCtives: The risk of venous thromboembolism (VTE) associated with antip-
sychotic use has been examined in a variety of populations but not in postmen-
opausal women prone to VTE. This study aimed to assess the VTE risk related 
to antipsychotics after menopause. Methods: A nested case-control study of 
271,198 women aged ≧ 50 years was conducted analyzing data from the Taiwan 
